Latest News for: edgewise

Edit

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and ...

Montana Standard 14 Jul 2026
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — ... .
Edit

Servier completes the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business (Day One Biopharmaceuticals Inc)

Public Technologies 13 Jul 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 133056561) .
Edit

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Canada Newswire 13 Jul 2026
SURESNES, France, July 13, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc.
Edit

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline (Form 8-K) (Edgewise Therapeutics Inc)

Public Technologies 13 Jul 2026
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline ... Boulder, Colo., (July 13, 2026) - Edgewise Therapeutics, Inc ... About Edgewise Therapeutics.
Edit

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

PR Newswire 13 Jul 2026
— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — ... BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc ... About Edgewise Therapeutics.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Edgewise Therapeutics Inc)

Public Technologies 02 Jul 2026
Edgewise Therapeutics, Inc ... C/O EDGEWISE THERAPEUTICS, INC., 1715 38TH STREET 3 ... C/O EDGEWISE THERAPEUTICS, INC ... on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc ... Edgewise Therapeutics Inc.
Edit

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

The Daily Sentinel 01 Jul 2026
("Edgewise" or the "Company"), (Nasdaq ... 2026, Edgewise… .
Edit

Notice of Proposed Sale of Securities (Form 144) (Edgewise Therapeutics Inc)

Public Technologies 01 Jul 2026
). The text version of this document is not available ... Edgewise Therapeutics Inc.
Edit

12-Week Phase 2 CIRRUS-HCM Trial Top-line Data Event (Edgewise Therapeutics Inc)

Public Technologies 16 Jun 2026
). The text version of this document is not available ... Edgewise Therapeutics Inc.
Edit

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)

PR Newswire 16 Jun 2026
BOULDER, Colo., June 16, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc ... Members of the Edgewise management team will hold a live webcast on Tuesday, June 16, 2026, at 8.30 a.m ... The entire team at Edgewise is dedicated to our mission.
Edit

French pharma giant Servier buys Edgewise muscular dystrophy biz

Daily Camera 05 Jun 2026
BOULDER — Edgewise Therapeutics Inc. (Nasdaq.
Edit

Proxy Results (Form 8-K) (Edgewise Therapeutics Inc)

Public Technologies 05 Jun 2026
) Item 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. Edgewise Therapeutics, Inc. (the "Company") held its Annual Meeting of stockholders (the "Annual Meeting") on June 4, 2026 ... Proposal 1 ... Edgewise Therapeutics Inc ... (noodl.
Edit

Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business (Day One Biopharmaceuticals Inc)

Public Technologies 01 Jun 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 132160202) .
Edit

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline (Form 8-K) (Edgewise Therapeutics Inc)

Public Technologies 01 Jun 2026
Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline ... BOULDER, Colo., [June 1, 2026] - Edgewise Therapeutics, Inc ... About Edgewise Therapeutics.
Edit

Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business

PR Newswire 01 Jun 2026
... today announced that it has entered into an agreement to acquire the muscular dystrophy business of Edgewise Therapeutics Inc ... Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business.

Article Search

tools
×
×
×
×